基质金属蛋白酶抑制剂
生物信息学
MMP2型
计算生物学
药品
基质金属蛋白酶
化学
血管生成
药物发现
抗癌药
药理学
对接(动物)
医学
组合化学
生物化学
生物
癌症研究
护理部
下调和上调
基因
作者
Shankha Sanyal,Sk. Abdul Amin,Nilanjan Adhikari,Tarun Jha
出处
期刊:Future Medicinal Chemistry
[Newlands Press Ltd]
日期:2021-11-01
卷期号:13 (22): 1987-2013
被引量:8
标识
DOI:10.4155/fmc-2021-0262
摘要
MMP2, a Zn 2+ -dependent metalloproteinase, is related to cancer and angiogenesis. Inhibition of this enzyme might result in a potential antimetastatic drug to leverage the anticancer drug armory. In silico or computer-aided ligand-based drug design is a method of rational drug design that takes multiple chemometrics (i.e., multi-quantitative structure–activity relationship methods) into account for virtually selecting or developing a series of probable selective MMP2 inhibitors. Though existing matrix metalloproteinase inhibitors have shown plausible pan-matrix metalloproteinase (MMP) activity, they have resulted in various adverse effects leading to their being rescinded in later phases of clinical trials. Therefore a review of the ligand-based designing methods of MMP2 inhibitors would result in an explicit route map toward successfully designing and synthesizing novel and selective MMP2 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI